Related Experiment Video

Updated: Aug 15, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells

Yao-Ting Huang1, Shiow-Lin Pan, Jih-Hwa Guh

  • 1Pharmacological Institute, College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Taipei 100, Taiwan. cmteng@ntumc.org.

Molecular Cancer Therapeutics
|October 18, 2005
PubMed

Insights

The anticancer compound YC-1 induces apoptosis and suppresses nuclear factor-kappaB (NF-kappaB) activation in prostate cancer cells. YC-1 also demonstrated significant antitumor effects in preclinical models, warranting further investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The anticancer potential of the indazole compound YC-1 is recognized, but its precise molecular targets and mechanisms in cancer remain incompletely understood.
  • Prostate cancer, particularly hormone-refractory metastatic disease, presents a significant therapeutic challenge, necessitating novel treatment strategies.

Purpose of the Study:

  • To investigate whether YC-1 directly induces apoptosis in human prostate cancer PC-3 cells.
  • To elucidate the underlying mechanisms of YC-1-mediated cell death, focusing on key signaling pathways.
  • To evaluate the in vivo antitumor efficacy of YC-1 in a preclinical xenograft model.

Main Methods:

  • Cell viability was assessed using the MTT assay.
  • Apoptosis was quantified via 4',6-diamidino-2-phenylindole staining and cell cycle analysis by flow cytometry.
  • Activation of caspase-3, poly(ADP-ribose) polymerase cleavage, and nuclear factor-kappaB (NF-kappaB) signaling pathway components (p65 translocation, IkappaBalpha phosphorylation) were analyzed.

Main Results:

  • YC-1 significantly inhibited PC-3 cell proliferation in a dose- and time-dependent manner.
  • YC-1 induced apoptosis, evidenced by chromatin condensation and increased hypodiploid sub-G0-G1 phase population.
  • YC-1 treatment led to caspase-3 activation, PARP cleavage, and suppression of NF-kappaB/p65 nuclear translocation and activation, alongside inhibition of IkappaBalpha phosphorylation.

Conclusions:

  • YC-1 effectively induces apoptosis and suppresses NF-kappaB activation in hormone-refractory prostate cancer cells.
  • YC-1 exhibits significant antitumor activity in vivo, reducing tumor xenograft growth.
  • YC-1 represents a promising therapeutic agent for hormone-refractory prostate cancer, meriting further clinical investigation.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...